Better understanding of the genetic effects of NF-κB-dependent inflammatory pathways is essential for further research on modulation of NF-κB activity by specific inhibitors, such as small molecule inhibitors of cRel, as an adjuvant treatment for sepsis [52, 53]. This evidence concerns the gene NFKB1 and Sepsis.